93 related articles for article (PubMed ID: 24440159)
21. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
[TBL] [Abstract][Full Text] [Related]
22. Knowledge about Human Papillomavirus and Time to Complete Vaccination among Vulnerable Female Youth.
Nagpal J; Linares LO; Weiss J; Schlecht NF; Shankar V; Braun-Courville D; Nucci-Sack A; Strickler HD; Burk RD; Diaz A
J Pediatr; 2016 Apr; 171():122-7. PubMed ID: 26846571
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.
Yih WK; Greene SK; Zichittella L; Kulldorff M; Baker MA; de Jong JL; Gil-Prieto R; Griffin MR; Jin R; Lin ND; McMahill-Walraven CN; Reidy M; Selvam N; Selvan MS; Nguyen MD
Vaccine; 2016 Jan; 34(1):172-8. PubMed ID: 26549364
[TBL] [Abstract][Full Text] [Related]
24. Adverse events following immunization in Ontario's female school-based HPV program.
Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
[TBL] [Abstract][Full Text] [Related]
25. Patient adherence to three dose completion of the quadrivalent human papillomavirus (HPV) vaccine in a private practice.
Rubin RF; Kuttab HM; Rihani RS; Reutzel TJ
J Community Health; 2012 Dec; 37(6):1145-50. PubMed ID: 22752532
[TBL] [Abstract][Full Text] [Related]
26. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
[TBL] [Abstract][Full Text] [Related]
27. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
Naleway AL; Crane B; Smith N; Daley MF; Donahue J; Gee J; Greene SK; Harrington T; Jackson LA; Klein NP; Tseng HF; Vellozzi C; Weintraub ES;
Vaccine; 2016 Jan; 34(1):167-71. PubMed ID: 26549361
[TBL] [Abstract][Full Text] [Related]
28. Staying on track: a cluster randomized controlled trial of automated reminders aimed at increasing human papillomavirus vaccine completion.
Patel A; Stern L; Unger Z; Debevec E; Roston A; Hanover R; Morfesis J
Vaccine; 2014 May; 32(21):2428-33. PubMed ID: 24631099
[TBL] [Abstract][Full Text] [Related]
29. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
Lazcano-Ponce E; Stanley M; Muñoz N; Torres L; Cruz-Valdez A; Salmerón J; Rojas R; Herrero R; Hernández-Ávila M
Vaccine; 2014 Feb; 32(6):725-32. PubMed ID: 24355090
[TBL] [Abstract][Full Text] [Related]
30. The influence of deductible health plans on receipt of the human papillomavirus vaccine series.
Roblin DW; Ritzwoller DP; Rees DI; Carroll NM; Chang A; Daley MF
J Adolesc Health; 2014 Mar; 54(3):275-81. PubMed ID: 24560035
[TBL] [Abstract][Full Text] [Related]
31. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.
Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ
J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261
[TBL] [Abstract][Full Text] [Related]
32. HPV vaccine recommendations.
Committee on Infectious Diseases
Pediatrics; 2012 Mar; 129(3):602-5. PubMed ID: 22371460
[TBL] [Abstract][Full Text] [Related]
33. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization.
Chao C; Velicer C; Slezak JM; Jacobsen SJ
Mayo Clin Proc; 2009 Oct; 84(10):864-70. PubMed ID: 19797775
[TBL] [Abstract][Full Text] [Related]
34. Quantitative and qualitative assessment of an all-inclusive postpartum human papillomavirus vaccination program.
Berenson AB; Hirth JM; Kuo YF; Rupp RE
Am J Obstet Gynecol; 2021 May; 224(5):504.e1-504.e9. PubMed ID: 33248134
[TBL] [Abstract][Full Text] [Related]
35. Underinsurance and adolescent immunization delivery in the United States.
Smith PJ; Lindley MC; Shefer A; Rodewald LE
Pediatrics; 2009 Dec; 124 Suppl 5():S515-21. PubMed ID: 19948583
[TBL] [Abstract][Full Text] [Related]
36. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009.
Dorell CG; Stokley S; Yankey D; Markowitz LE
Vaccine; 2012 Jan; 30(3):503-5. PubMed ID: 22119587
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors.
Ganry O; Bernin-Mereau AS; Gignon M; Merlin-Brochard J; Schmit JL
Rev Epidemiol Sante Publique; 2013 Oct; 61(5):447-54. PubMed ID: 24016739
[TBL] [Abstract][Full Text] [Related]
38. Early lessons learned from extramural school programs that offer HPV vaccine.
Hayes KA; Entzel P; Berger W; Caskey RN; Shlay JC; Stubbs BW; Smith JS; Brewer NT
J Sch Health; 2013 Feb; 83(2):119-26. PubMed ID: 23331272
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine uptake among males 11-26 years in United States: findings from the National Health and Nutrition Examination Survey, 2011-2012.
Pierre-Victor D; Mukherjee S; Bahelah R; Madhivanan P
Vaccine; 2014 Nov; 32(49):6655-8. PubMed ID: 25446825
[TBL] [Abstract][Full Text] [Related]
40. Pain in adolescent girls receiving human papillomavirus vaccine with concomitantly administered vaccines.
Walter EB; Kemper AR; Dolor RJ; Dunne EF
Pediatr Infect Dis J; 2015 Feb; 34(2):200-2. PubMed ID: 25170553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
